On April 21, China’s leading pharmaceutical equipment manufacturer Truking Technology Limited(300358) released its annual report for 2021, with an annual operating revenue of 5.26 billion yuan, a year-on-year increase of 47.08%; The net profit attributable to the parent company was 566 million yuan, a year-on-year increase of 182.45%.
Since 2019, with the rise of new fields such as biological drugs and new therapies such as cell and gene therapy, the pharmaceutical equipment industry has entered a new round of growth Truking Technology Limited(300358) achieved rapid growth in performance for two consecutive years, of which the net profit increased by 207.62% in 2020.
According to the data, at the end of Truking Technology Limited(300358) 2021, the contract liabilities reached 2.662 billion yuan, a significant increase over previous periods, which means that the company has strong downstream demand and sufficient orders on hand. According to the annual report, Truking Technology Limited(300358) annual new orders exceeded 9 billion yuan, and the orders on hand at the end of the year exceeded 7 billion yuan. This provides a strong guarantee for the performance growth of Truking Technology Limited(300358) 2022 and subsequent years.
In 2021, Truking Technology Limited(300358) further improved the layout of bioengineering product line, laying a foundation for the company to grasp the biopharmaceutical market opportunity and expand the application scope of high-end equipment. At present, Truking Technology Limited(300358) has the ability to provide solutions for the whole process of biological drugs.
During the reporting period, Truking Technology Limited(300358) set up subsidiaries truking siute and truking microsphere, actively arranged the front-end of bioengineering, and completed the layout of biological front-end equipment and process solutions such as disposable bioreactor, disposable liquid preparation system, ultrafiltration chromatography purification, stainless steel reactor and filler.
In terms of vaccine equipment, Truking Technology Limited(300358) ‘s aseptic packaging and intelligent detection back package and other middle and rear stage products are widely used in covid-19 vaccine manufacturers such as Zhongsheng group, zhifeilong Kema, Beijing Kexing, Cansino Biologics Inc(688185) and so on. Subsequently, the company’s middle and rear product line is expected to further open the growth space of high-end equipment and promote the expansion of overseas markets with the full international competitiveness of relevant products.
According to the data, 51 newly authorized invention patents were added in Truking Technology Limited(300358) 2021, including 49 Chinese inventions and 2 PCT international inventions. By the end of 2021, Truking Technology Limited(300358) had 2395 valid patents, 20 valid PCT international patents and 193 software copyrights.
Truking Technology Limited(300358) said that in 2022, the company will strengthen efforts to maintain China’s leading edge in aseptic sub packaging and packaging products after testing; Focus on the development of biomedical equipment, especially biopharmaceutical front-end bioreactor and its disposable Technology (SUT) products, consumables, packaging materials and accessories; Establish an innovative drug equipment development team to develop new intelligent products.
Truking Technology Limited(300358) disclosed the medium and long-term development plan in the annual report for the first time. Based on pharmaceutical equipment, the company will expand to its associated process consumables, packaging materials, auxiliary materials and process engineering, supplemented by informatization, intelligent manufacturing and verification, and gradually transition from equipment solutions to technical solutions. Around 2030, the company will become one of the world’s leading pharmaceutical equipment enterprises with sales of about 20 billion yuan.
